Trial Profile
A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Acimtamig (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; First in man
- Sponsors Affimed Therapeutics
- 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
- 24 Jun 2013 Results presented at 12th International Conference on Malignant Lymphoma, according to an Affimed Therapeutics media release.
- 29 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.